Evaxion A/S vs Molecular Partners
EVAX and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EVAX and MOLN compare
Evaxion A/S grew revenue faster over the last twelve months (125% versus −100% for Molecular Partners).
Evaxion A/S scores higher on the StockData Score (2 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EVAX | MOLN |
|---|---|---|
| Size and price | ||
| Share price | $2.91 | $3.09 |
| Change, 1 year | −54.4% | −27.3% |
| Change, 5 years | −99.0% | −70.4% |
| Beta (5Y) | 1.24 | 0.90 |
| Employees | 45 | 34 |
| StockData Score | ||
| Total score | 2 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 125% (better) | −100% |
| Profitability | ||
| Operating margin | −123% | – |
| Net margin | −102% | – |
| FCF margin | −88.2% | – |
| Financial health | ||
| Interest coverage | −2.3× (better) | −11.5× |
| Current ratio | 5.06 | 7.27 (better) |
| Piotroski F-score | 5 | – |
| Ownership | ||
| Held by institutions | 0.38% | 8.9% |
| Held by insiders | 3.5% | 0.00% |
Go deeper
- EVAX stock overview
- EVAX income statement
- EVAX valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.